Literature DB >> 8827972

The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.

L B Russell1, M R Gold, J E Siegel, N Daniels, M C Weinstein.   

Abstract

OBJECTIVE: To develop consensus-based recommendations guiding the conduct of cost-effectiveness analysis (CEA) to improve the comparability and quality of studies. The recommendations apply to analyses intended to inform the allocation of health care resources across a broad range of conditions and interventions. This article, first in a 3-part series, discusses how this goal affects the conduct and use of analyses. The remaining articles will outline methodological and reporting recommendations, respectively. PARTICIPANTS: The Panel on Cost-Effectiveness in Health and Medicine, a nonfederal panel with expertise in CEA, clinical medicine, ethics, and health outcomes measurement, was convened by the US Public Health Service (PHS). EVIDENCE: The panel reviewed the theoretical foundations of CEA, current practices, and alternative procedures for measuring and assigning values to resource use and health outcomes. CONSENSUS PROCESS: The panel met 11 times during 2 1/2 years with PHS staff and methodologists from federal agencies. Working groups brought issues and preliminary recommendations to the full panel for discussion. Draft recommendations were circulated to outside experts and the federal agencies prior to finalization.
CONCLUSIONS: The panel's recommendations define a "reference case" cost-effectiveness analysis, a standard set of methods to serve as a point of comparison across studies. The reference case analysis is conducted from the societal perspective and accounts for benefits, harms, and costs to all parties. Although CEA does not reflect every element of importance in health care decisions, the information it provides is critical to informing decisions about the allocation of health care resources.

Entities:  

Keywords:  Health Care and Public Health; Panel on Cost-Effectiveness in Health and Medicine

Mesh:

Year:  1996        PMID: 8827972

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  254 in total

Review 1.  Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies?

Authors:  C Bombardier; A Maetzel
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Cost utility analysis of radiographic screening for an orbital foreign body before MR imaging.

Authors:  D J Seidenwurm; C H McDonnell; N Raghavan; J Breslau
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

3.  Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?

Authors:  Andreas Laupacis
Journal:  CMAJ       Date:  2002-01-08       Impact factor: 8.262

Review 4.  Criteria for evaluating evidence on public health interventions.

Authors:  L Rychetnik; M Frommer; P Hawe; A Shiell
Journal:  J Epidemiol Community Health       Date:  2002-02       Impact factor: 3.710

Review 5.  The limited incorporation of economic analyses in clinical practice guidelines.

Authors:  Joel F Wallace; Scott R Weingarten; Chiun-Fang Chiou; James M Henning; Andriana A Hohlbauch; Margaret S Richards; Nicole S Herzog; Lior S Lewensztain; Joshua J Ofman
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

6.  Acknowledgment of uncertainty: a fundamental means to ensure scientific and ethical validity in clinical research.

Authors:  B Djulbegovic
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

7.  Economic analysis of randomized, controlled trials.

Authors:  G H Lyman
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

Review 8.  AIDS policy modeling for the 21st century: an overview of key issues.

Authors:  M S Rauner; M L Brandeau
Journal:  Health Care Manag Sci       Date:  2001-09

9.  Using simulation for AIDS policy modeling: benefits for HIV/AIDS prevention policy makers in Vienna, Austria.

Authors:  Marion S Rauner
Journal:  Health Care Manag Sci       Date:  2002-04

10.  The role of cost-consequence analysis in healthcare decision-making.

Authors:  J A Mauskopf; J E Paul; D M Grant; A Stergachis
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.